|Bid||12.82 x 3200|
|Ask||12.85 x 1300|
|Day's Range||12.61 - 13.15|
|52 Week Range||4.65 - 14.90|
|Beta (3Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.60|
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In 2016 Chris Linthwaite was appointed CEO of Fluidigm Corporation (NASDAQ:FLDM). This report will, first, examine...
Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report first quarter 2019 financial results on Thursday, May 2, 2019, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on May 2, 2019, to discuss first quarter financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.
Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.
Glaukos' (GKOS) strong pipeline is indicative of brighter prospects ahead. However, cutthroat competition in the medical-device industry is worrisome.
SOUTH SAN FRANCISCO, Calif., March 28, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through.
Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the introduction of the Maxpar® Direct™ Immune Profiling System. Setting the new standard in immune profiling, the system empowers researchers to easily quantify 37 different immune cell populations from human peripheral blood mononuclear cells (PBMC) and whole blood using a simple single-tube workflow with automated five-minute results reporting. In the past two years alone, clinical trials utilizing immune cell profiling have grown by more than 30 percent, with more than 35,000 patients enrolled.
As drug giants AbbVie and Merck and biotech progenitor Genentech establish themselves in South San Francisco, a much smaller life sciences company has scored the top four floors of the new, high-profile Genesis South San Francisco along Highway 101.
Fluidigm Corp creates, manufactures, and markets technologies and life-science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon microfluidics and mass cytometry technologies. Fluidigm Corp had annual average EBITDA growth of 19.90% over the past ten years. Warning! GuruFocus has detected 7 Warning Signs with FLDM.
A caller during the Lightning Round of "Mad Money" Monday asked Jim Cramer about Fluidigm Corp. Let's check out the charts of Fluidigm, which makes microfluidic systems for the life science and agricultural biotechnology industries. In this daily bar chart of FLDM, below, we can see that prices have rallied nicely from the middle of June.
Fluidigm Corporation (FLDM) today announced that Colin McCracken has joined the company as its Chief Commercial Officer. McCracken will be responsible for leading all commercial activities, driving revenue growth in new and existing markets and expanding the company’s global reach. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite, McCracken will advance Fluidigm’s commercialization infrastructure and organization toward further market adoption of the company’s products, particularly in the growing scientific community studying the human immune system.
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Fluidigm Corporation (FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 12, 2019, under Fluidigm’s 2017 Inducement Award Plan (Plan), as a material inducement to seven individuals entering into employment with Fluidigm. In connection with the individuals entering into employment with Fluidigm as new employees, none of whom were previously employees or directors of Fluidigm, the individuals received awards totaling an aggregate of 48,900 restricted stock units (RSU Awards).
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In December 2018, Fluidigm Corporation (NASDAQ:FLDM) announcedRead More...